Predictive modeling of treatment resistant depression using data from STAR*D and an independent clinical study
暂无分享,去创建一个
Jieping Ye | Zhi Nie | Vaibhav A Narayan | Srinivasan Vairavan | Qingqin S Li | Jieping Ye | V. Narayan | Qingqin S. Li | S. Vairavan | Z. Nie
[1] M. Weissman,et al. Moderation of the Relationship Between Reward Expectancy and Prediction Error-Related Ventral Striatal Reactivity by Anhedonia in Unmedicated Major Depressive Disorder: Findings From the EMBARC Study. , 2015, The American journal of psychiatry.
[2] D J Kupfer,et al. Exactly what does the Hamilton Depression Rating Scale measure? , 1993, Journal of psychiatric research.
[3] Julien Mendlewicz,et al. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. , 2007, The Journal of clinical psychiatry.
[4] Aart H Schene,et al. Staging methods for treatment resistant depression. A systematic review. , 2012, Journal of affective disorders.
[5] M. Hamilton. A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.
[6] Meindert Danhof,et al. Sensitivity of the individual items of the Hamilton depression rating scale to response and its consequences for the assessment of efficacy. , 2008, Journal of psychiatric research.
[7] D. Kupfer,et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. , 2004, Controlled clinical trials.
[8] P. Bech,et al. QUANTITATIVE RATING OF DEPRESSIVE STATES , 1975, Acta psychiatrica Scandinavica.
[9] Kenji Hashimoto,et al. Low Openness on the Revised NEO Personality Inventory as a Risk Factor for Treatment-Resistant Depression , 2013, PloS one.
[10] Huan Liu,et al. Chi2: feature selection and discretization of numeric attributes , 1995, Proceedings of 7th IEEE International Conference on Tools with Artificial Intelligence.
[11] R. Perlis. A Clinical Risk Stratification Tool for Predicting Treatment Resistance in Major Depressive Disorder , 2013, Biological Psychiatry.
[12] A. Kuk,et al. Recursive subsetting to identify patients in the STAR*D: a method to enhance the accuracy of early prediction of treatment outcome and to inform personalized care. , 2010, The Journal of clinical psychiatry.
[13] M. Weissman,et al. Accounting for Dynamic Fluctuations across Time when Examining fMRI Test-Retest Reliability: Analysis of a Reward Paradigm in the EMBARC Study , 2015, PloS one.
[14] Marcin Siwek,et al. Risk factors of treatment resistance in major depression: association with bipolarity. , 2010, Journal of affective disorders.
[15] Verinder Sharma,et al. A closer look at treatment resistant depression: is it due to a bipolar diathesis? , 2005, Journal of affective disorders.
[16] Aart H Schene,et al. The Dutch Measure for quantification of Treatment Resistance in Depression (DM-TRD): an extension of the Maudsley Staging Method. , 2016, Journal of affective disorders.
[17] M. Leboyer,et al. Risk factors for treatment resistance in unipolar depression: a systematic review. , 2015, Journal of affective disorders.
[18] P Bech,et al. The Hamilton Depression Scale , 1981, Acta psychiatrica Scandinavica.
[19] W. Maier,et al. Comparative analysis of observer depression scales , 1985, Acta psychiatrica Scandinavica.
[20] S. S. Young,et al. Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment , 1993 .
[21] Qingyang Li,et al. Melancholic Depression Prediction by Identifying Representative Features in Metabolic and Microarray Profiles with Missing Values , 2015, Pacific Symposium on Biocomputing.
[22] M. Hamilton,et al. Development of a rating scale for primary depressive illness. , 1967, The British journal of social and clinical psychology.
[23] D. Kupfer,et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. , 2003, The Psychiatric clinics of North America.
[24] S. Geer,et al. Correlated variables in regression: Clustering and sparse estimation , 2012, 1209.5908.
[25] I. Heuser,et al. Improving depression severity assessment--II. Content, concurrent and external validity of three observer depression scales. , 1988, Journal of psychiatric research.
[26] Li Shen,et al. Dimension reduction-based penalized logistic regression for cancer classification using microarray data , 2005, IEEE/ACM Transactions on Computational Biology and Bioinformatics.
[27] D. Kupfer,et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. , 2006, The American journal of psychiatry.
[28] Michael Berk,et al. Application of the Gradient Boosted method in randomised clinical trials: Participant variables that contribute to depression treatment efficacy of duloxetine, SSRIs or placebo. , 2014, Journal of affective disorders.
[29] Leo Breiman,et al. Random Forests , 2001, Machine Learning.
[30] H. Zou,et al. Regularization and variable selection via the elastic net , 2005 .
[31] Gaël Varoquaux,et al. Scikit-learn: Machine Learning in Python , 2011, J. Mach. Learn. Res..
[32] Trevor Hastie,et al. Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.
[33] Harlan M. Krumholz,et al. Reevaluating the Efficacy and Predictability of Antidepressant Treatments: A Symptom Clustering Approach , 2017, JAMA psychiatry.
[34] Marcia K. Johnson,et al. Cross-trial prediction of treatment outcome in depression: a machine learning approach. , 2016, The lancet. Psychiatry.
[35] Roumen Milev,et al. The Canadian Biomarker Integration Network in Depression (CAN-BIND): advances in response prediction. , 2012, Current pharmaceutical design.
[36] Kenji Hashimoto,et al. Personality Traits as Risk Factors for Treatment-Resistant Depression , 2013, PloS one.
[37] B. Carroll,et al. ‘Effects of Risperidone Augmentation in Patients with Treatment-Resistant Depression: Results of Open-Label Treatment Followed by Double-Blind Continuation.’ , 2008, Neuropsychopharmacology.
[38] H Wetzel,et al. Improving depression severity assessment--I. Reliability, internal validity and sensitivity to change of three observer depression scales. , 1988, Journal of psychiatric research.
[39] Sidney H. Kennedy,et al. Measuring the severity of depression and remission in primary care: validation of the HAMD-7 scale , 2005, Canadian Medical Association Journal.
[40] Quentin J M Huys,et al. Neural Correlates of Three Promising Endophenotypes of Depression: Evidence from the EMBARC Study , 2016, Neuropsychopharmacology.
[41] M. Trivedi,et al. Identifying predictors, moderators, and mediators of antidepressant response in major depressive disorder: neuroimaging approaches. , 2015, The American journal of psychiatry.
[42] Gustavo Turecki,et al. What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials , 2007, European Neuropsychopharmacology.
[43] Maurizio Fava,et al. Brief, unidimensional melancholia rating scales are highly sensitive to the effect of citalopram and may have biological validity: implications for the research domain criteria (RDoC). , 2014, Journal of affective disorders.
[44] Ruud Boessen,et al. Comparing HAMD(17) and HAMD subscales on their ability to differentiate active treatment from placebo in randomized controlled trials. , 2013, Journal of affective disorders.
[45] M H Trivedi,et al. Factor structure and dimensionality of the two depression scales in STAR*D using level 1 datasets. , 2011, Journal of Affective Disorders.